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Abstract
Disulfide bonds formed between a pair of oxidized cysteines are important to the structural 
integrity and proper folding of many proteins. Accordingly, Nature has evolved several sys-
tems for the genesis and maintenance of such bonds. Beginning with the discovery of protein 
disulfide isomerase, which provided the first evidence for enzyme-catalyzed disulfide-bond 
formation, many years of research have resulted in the explication of the complex network of 
electron transport pathways needed for this process. Herein, we take a historical approach in 
describing the elucidation of disulfide-bond formation in E. coli. We frame this topic in the 
context of genome sequencing eras. The first section describes the discovery of eukaryotic 
protein disulfide isomerase and the subsequent research that followed from the early 1960s 
to the early 1990s, a time period we have named the pre-genomic sequencing era. The second 
section details the renaissance in research on disulfide-bond formation in the periplasm of 
prokaryotes, fueled by bacterial genetic screens and the development of genomic sequenc-
ing technology. Accordingly, we have named this section the genomic sequencing era, which 
ranges from the early 1990s to approximately 2010. The final section outlines the use of bac-
terial genetic screens to select for new oxidoreductase enzymes and their potential uses in 
 biotechnological and pharmaceutical applications. This era we have dubbed the  post-genomic 
sequencing era, and we envision it to represent the future of research on oxidative folding.
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1. Introduction: covalent bonds in proteins
The amino acids comprising a protein are covalently linked by peptide bonds, which collec-
tively form the “backbone” of the protein. These bonds are the most prevalent covalent links 
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between amino acids in proteins and form the foundations that support protein secondary and 
tertiary structures. In addition to peptide bonds, disulfide bonds are the second most common 
covalent bonds between amino acids. Disulfide bonds are sulfur-sulfur bonds formed within a 
protein when the thiol (-SH) groups of two cysteine residues are each oxidized, resulting in the 
net loss of two electrons to an oxidizing agent. Other names for these bonds include S-S bonds, 
disulfide bridges, disulfide crosslinks, and simply disulfides/disulphides. Disulfide bonds 
play three main roles in proteins as signal relays (signaling disulfide bonds), as active site resi-
dues in enzymatic catalysis (catalytic disulfide bonds), and as structural supports (structural 
disulfide bonds). Signaling disulfide bonds act as environmental redox readouts, such as those 
observed in the OxyR transcription factor (reactive oxygen species sensing), the ArcAB system 
(senses changes in respiratory growth conditions), and the antisigma factor RsrA (activates 
cytoplasmic oxidative stress response) [1–3]. Catalytic disulfide bonds act as active site resi-
dues in oxidoreductases such as DsbA and DsbC, which catalyze the oxidation and isomeriza-
tion of disulfide bonds, respectively [4–6]. While signaling and catalytic disulfide bonds are 
important, the primary functions of structural disulfide bonds are to facilitate protein folding 
and to stabilize protein tertiary structure, which will be the focus of this chapter.
2. Disulfide-bond research during the pre-genomic sequencing era
The pre-genomic sequencing era focuses on the research surrounding disulfide-bond forma-
tion conducted in the early 1960s through the early 1980s. The work of Anfinsen, Straub, 
and others on the disulfide-bond formation in Ribonuclease A (RNase A) provided the initial 
impetus behind studying this process and is described below.
The roles of structural disulfide bonds in protein folding and stability are well exem-
plified and characterized in the protein RNase A, which contains a total of four disulfide 
bonds (Cys26-Cys84, Cys40-Cys95, Cys58-Cys110, and Cys65-Cys74) that contribute to the 
 “legendary” stability of RNase A [7]. Indeed, the classic isolation and purification protocol 
of active RNase A from bovine pancreas calls for extremely harsh conditions in the context 
of proteins: treatment of pancreatic tissue with 0.25 N sulfuric acid at 5°C for 1 day, followed 
by ammonium sulfate precipitation and boiling in 20% saturated ammonium sulfate at pH 
3.0 for 5–10 min [8]. While these purification conditions disrupt noncovalent interactions, the 
covalent nature of disulfide bonds allows them to survive such treatments, thereby imparting 
structural stability to the protein. Disulfide bonds also constrain the number of conformations 
an unfolded protein can adopt, which destabilizes the unfolded state relative to the folded 
state [9]. In fact, the stability of properly folded RNase A has been estimated to be 8 kcal/
mol greater than the unfolded state [10], and the four disulfide bonds collectively contribute 
an estimated 19 kcal/mol to this stability [11]. While it is clear that structural disulfide bonds 
play important roles in maintaining the overall integrity of a protein, especially in the case of 
RNase A, they also serve to aid in the initial folding and refolding of a protein.
Seminal experiments conducted in the early 1960s on RNase A led to the idea that all of the 
information required to form the correct structures and disulfide bonds of small, globular 
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 proteins is contained within its amino acid sequence [12–17]. Evidence supporting this idea—
now known as Anfinsen’s dogma—was obtained from in vitro experiments in which RNase A 
was denatured and completely reduced to yield an unstructured polypeptide chain containing 
eight cysteine residues. Removal of denaturant and reducing agent and subsequent incubation 
of the enzyme open to atmosphere resulted in relatively rapid and spontaneous formation of 
disulfide bonds—formed by oxidation via molecular oxygen—followed by much slower recov-
ery of RNase activity. Under optimized conditions, the halftime required for recovery of RNase 
activity was 20 min. This apparent lag phase between disulfide-bond formation and recovery 
of activity suggested that spontaneous disulfide-bond formation resulted in incorrect cysteine 
pairing and that the recovery of activity required additional time for disulfide interchange and 
proper formation to occur [16]. This also suggested that a system for oxidizing and reshuffling 
disulfide bonds existed in vivo, since the 20-min recovery of activity observed in vitro was far 
too slow to be operative in the cell.
Shortly after demonstrating the spontaneous formation of disulfide bonds in reduced RNase 
A, Anfinsen and colleagues identified an enzyme, isolated from rat liver microsomes, that 
stimulated RNase A reactivation, with recovery of activity requiring a halftime of 4.5 min. 
This discovery confirmed the existence of an in vivo system capable of catalyzing the  formation 
of the correct disulfide bonds to yield the active enzyme [18]. In addition to the rat liver, 
the same enzyme had been identified by Venetianer and Straub in chicken, pig, and pigeon 
pancreatic tissue [17]. Further studies in which the microsomal enzyme was incubated with 
reduced egg white lysozyme as a substrate—which contains four disulfide bonds required 
for its activity—demonstrated similar recovery of activity. Due to the recovery of activity in 
RNase A from both bovine pancreas and rat liver and in egg white lysozyme, the substrate 
specificity of the enzyme appeared to be rather low. As a result, this enzyme was speculated 
to be a general mediator of “sulfhydryl-disulfide exchange” in vivo. The catalyzed reaction is 
driven by the release of free energy attained upon folding substrates from unorganized con-
formations to their more stable native structures [18–20]. Furthermore, the enzyme catalyzing 
sulfhydryl-disulfide exchange enzyme was shown to possess a DTT-sensitive disulfide bond 
that was likely to be involved in catalysis [19]. In 1973, nearly 6 years after its identification, 
the microsome-associated enzyme that catalyzed sulfhydryl-disulfide exchange was given a 
name: protein disulfide isomerase (PDI).
In the early 1980s, several studies demonstrated a correlation between PDI activity and 
the synthesis of disulfide-bond containing proteins in specialized cells and tissues [21, 22]. 
However, it was not until 1983—nearly 10 years after its naming—that PDI was purified to 
homogeneity and biochemically characterized [23]. Homogenous PDI was shown to catalyze 
the reduction of disulfide bonds in insulin in vitro. This result demonstrated that PDI could 
catalyze both disulfide-bond formation and reduction, and led some to question whether the 
name ‘protein disulfide isomerase’ was a misnomer. Based on the physiological evidence sur-
rounding PDI—its distribution in tissue with great abundance of disulfide-bonded proteins 
[22]; its localization in the endoplasmic reticulum, where many disulfide-bonded proteins are 
synthesized; and its broad substrate specificity—in conjunction with findings showing PDI to 
be a relatively poor reductase, the name PDI was retained and is still in use [24].
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The advent of genome sequencing and PCR in the later 1980s caused a shift from eukaryotic 
PDI studies to research centered on bacterial disulfide-bond formation, which is detailed in 
the following section. It should be noted that Anfinsen’s idea that the amino acid sequence 
of a protein encodes all of the information necessary for its proper folding was not fully cor-
rect. Even though Anfinsen shared the 1972 Nobel Prize in Chemistry with Stanford Moore 
and William H. Stein, the following decades of his and others’ research showed that disul-
fide-bond formation and protein folding are, in fact, catalyzed processes in vivo. The work 
surrounding RNase A refolding and the elucidation of PDI serves as an example wherein 
the true answers to fundamental questions often require far more research to unravel their 
complexities.
3. Genome sequencing enables a great leap forward in bacterial redox 
biology research
The eponymous Sanger DNA sequencing method was developed by Frederick Sanger and 
colleagues in 1977 [25]. This method is based on selective incorporation of chain-terminat-
ing dideoxynucleotides by DNA polymerases during in vitro DNA replication [26]. Sanger 
sequencing was the most widely utilized DNA sequencing technology until relatively 
recently. Gene sequencing became reasonably attainable with the 1986 release of a fully auto-
mated DNA sequencer made by Applied Biosystems. Around the same time, Kary Mullis of 
Cetus Corporation developed polymerase chain reaction (PCR) technology, which led to the 
first commercial PCR enzyme and thermal cycler systems available to scientists in 1987 [27]. 
Together, Sanger sequencing and the development of PCR technology ushered in the gene 
sequencing era and revolutionized molecular biology.
With the ability to sequence genes, in conjunction with the already rich field of bacterial 
genetics and its corresponding techniques, the stage was set for identifying genes involved 
in redox biology. Along these lines, a genetic selection in Escherichia coli designed to identify 
factors involved in protein translocation led to the serendipitous discovery of mutations in 
the dsbA gene that affected disulfide-bond formation [28]. The DsbA protein was isolated and 
demonstrated to catalyze disulfide-bond reduction using insulin as a substrate in vitro [28, 
29]. Later studies revealed DsbA to be a potent and sequential oxidant [30]. Specifically, DsbA 
forms disulfide bonds between sequential cysteines in proteins as they are translocated to the 
periplasm [31] (Figure 1). Collectively, these studies identified DsbA as the first periplasmic 
protein involved in disulfide-bond formation and paved the way for elucidating the disulfide-
bond forming machinery in E. coli.
A second protein involved in disulfide-bond formation was identified through genetic screens 
of resistance or sensitivity to strong reducing agents. In these screens, Tn10 insertion mutants 
sensitive to DTT and benzylpenicillin were mapped to a second gene, which was named dsbB 
[30, 32]. The dsbB gene product was later confirmed to specifically oxidize DsbA [33]. Since 
then, research in several laboratories has elucidated the electron transfer pathway through 
which approximately 40% of cell envelope proteins in E. coli obtain disulfide bonds [34–38] 
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(see Figure 1). Specifically, the DsbA protein transfers disulfide bonds to substrate proteins 
in the periplasm by accepting electrons from the substrate’s cysteine residues. As a result, 
the cysteine residues of DsbA become reduced and the protein must be oxidized for it to 
 catalyze another round of disulfide bond transfer [28, 29]. This oxidation reaction is carried 
out by DsbB, an inner membrane protein with two pairs of redox-active cysteines [30, 32]. The 
 electrons received by DsbB in its oxidation of DsbA are transferred to the pool of quinones 
within the inner membrane [37, 39–43]. Then, the reduced quinones are recycled by cyto-
chrome and terminal oxidases of the electron transport chain [42, 44–46]. Together, DsbA and 
DsbB act as the oxidation system for disulfide-bond formation in the periplasm (Figure 1). 
These two proteins form one part of the periplasmic disulfide-bond forming pathway; addi-
tional proteins, DsbC and DsbD, among others, play downstream roles in the fidelity of native 
disulfide bonds.
Figure 1. The disulfide-bond-forming pathways in the periplasm of E. coli. A protein containing four cysteines in their 
reduced (free thiol) states is translocated into the periplasm by the SecYEG translocon. (1). Oxidized DsbA catalyzes 
disulfide-bond formation either as the protein is translocated or after, resulting in sequential disulfide bonds in this 
protein. DsbA is then oxidized to its active state by DsbB. DsbB is oxidized by ubiquinone or menaquinone under 
aerobic or anaerobic conditions, respectively (not shown). (2). If the disulfide bonds formed by DsbA are misoxidized, 
reduced DsbC catalyzes their isomerization to yield the properly folded protein. (3). DsbD then reduces DsbC to its 
active state. DsbD is reduced by an electron cascade originating from NADPH and mediated by thioredoxin reductase 
and thioredoxin in the cytoplasm (not shown).
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The misoxidation of substrates by DsbA necessitates the existence of a system capable of isom-
erizing incorrect disulfide bonds to their correct linkages in prokaryotes. In E. coli, the isom-
erization of disulfide bonds in proteins is catalyzed by DsbC. The dsbC gene was discovered 
in 1994, shortly after the discovery of the dsbB gene, using the same genetic selection approach 
[47]. The dsbC gene product was characterized and was shown to contain two cysteines that 
reside in the CXXC motif generally found in oxidoreductases. Subsequently, DsbC was dem-
onstrated to catalyze disulfide-bond isomerization of substrates containing nonconsecutive 
disulfide bonds [48–51] (Figure 1). This substrate preference of DsbC was illustrated with two 
nearly identical E. coli proteins, phytase (AppA) and  glucose-1-phosphatase (Agp), which 
differ by the former containing a nonconsecutive disulfide bond, while the latter has only con-
secutive disulfide bonds. AppA was shown to be dependent on DsbC for proper folding into 
its active conformation, whereas Agp exhibited no dependence on DsbC until a nonconsecu-
tive disulfide bond placed similarly as that found in phytase was introduced [48]. To date, 
no exceptions to the substrate preference of DsbC have been found. Taken together, these 
results suggested that DsbC is a protein disulfide isomerase that catalyzes the rearrangement 
of misoxidized disulfide bonds, in particular, the rearrangement of nonconsecutive disulfide 
bonds. Thus, DsbA and DsbC work in parallel in maintaining the correct disulfide bonds in 
the periplasmic E. coli proteome. DsbA catalyzes disulfide-bond formation as the protein is 
translocated into the periplasm, resulting in the formation of consecutive disulfide bonds. In 
those proteins requiring nonconsecutive disulfide bonds, DsbC catalyzes the isomerization of 
misoxidized bonds to yield active enzymes. The exact details of substrate recognition and the 
in vivo mechanism of isomerization catalyzed by DsbC have yet to be elucidated. However, 
preliminary evidence suggests that certain correctly oxidized proteins may result not only 
from oxidation and isomerization but also from iterative cycles of reduction and oxidation 
by DsbA and DsbC [52]. Another protein, DsbG, shares 28% sequence identity with DsbC 
and exhibits protein disulfide isomerase activity, albeit on a more narrow scope of yet-to-be-
identified substrates [5, 53, 54].
Like DsbA, DsbC has a dedicated redox protein partner, named DsbD, which is responsible 
for maintaining it in its reduced state (Figure 1). The dsbD gene was discovered using the same 
genetic screens that led to the discoveries of both DsbB and DsbC [55]. The dsbD gene product 
consists of three domains: an N-terminal periplasmic domain, a transmembrane domain, and 
a C-terminal periplasmic thioredoxin-like domain that shares approximately 45% sequence 
homology with eukaryotic PDIs [56]. Each of the domains of DsbD contains a pair of con-
served cysteine residues that are redox active and essential for its function [56]. To maintain 
DsbC in its reduced state, DsbD channels reducing equivalents that are mediated through a 
cascade of disulfide-bond reductions starting with the reduction of thioredoxin reductase by 
NADPH [57, 58]. Thioredoxin reductase reduces thioredoxin, which then reduces the cyste-
ine pair in the transmembrane domain of DsbD [58, 59]. This reduced cysteine pair initiates 
the sequential reduction of disulfide bonds in the C-terminal and N-terminal DsbD domains, 
respectively [59]. The reduced N-terminal domain cysteines then reduce DsbC (Figure 1). 
Reduction of DsbC occurs only when it is dimeric [60, 61]. This substrate preference likely 
stems from the tertiary structure of the N-terminal domain of DsbD, which adopts a immuno-
globulin-like fold and places the active site in the antigen-binding-like region [62]. The tertiary 
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structure promotes the binding of the DsbC dimer and occludes the binding of the monomeric 
DsbA and DsbB proteins, thereby separating the oxidative and reductive pathways [63].
The formation of disulfide bonds is essential to the structural integrity and folding of pro-
teins that are vital in many biological processes. E. coli and other prokaryotes have evolved 
a complex network of electron transport chains and quality control systems to facilitate and 
ensure proper disulfide-bond formation in the form of the Dsb proteins described above. 
The discovery of these Dsb proteins, and the subsequent revival of interest in disulfide-bond 
formation in eukaryotes, would not have been realized without the powerful combination of 
well-designed, selective genetic screens to produce mutants and the ability to sequence the 
resulting mutated genes. With the advent of next-generation sequencing, we should expect 
further elucidation of the biological and chemical processes that we do not yet understand or 
have yet to be discovered.
4. Disulfide-bond research in the post-genomic sequencing era
Since 2008, the cost of genome sequencing has declined faster than predicted by Moore’s Law 
[64]. Currently, the cost of sequencing a genome is ~$1500, and the lofty $1000/genome goal 
is within reach. Due to the radical drop in DNA sequencing costs, a multitude of laboratories 
and private and government institutions have completed the sequencing of approximately 
30,000 bacterial genomes [65]. This wealth of data is currently being used for a variety of 
biotechnological and clinical purposes including diagnostics, public health benefits, and bio-
surveillance/epidemiological studies [66, 67]. Accordingly, we have termed this time period 
as the “post-genomic sequencing era” to represent research that uses sequenced genomes, 
metagenomes, and environmental samples to search for novel enzymes and pathways and to 
predict the redox biology of bacteria.
4.1. Hunting for new disulfide-bond forming enzymes in the genomic landscape
One of the first examples of the use of sequenced genomes to predict and identify novel disul-
fide-bond forming pathways was conducted by Todd Yeates and colleagues [68–70]. They 
hypothesized that organisms rich in disulfide-bonded proteins would have a propensity to 
encode for proteins with an even number of cysteine residues, since an odd number might 
cause formation of aberrant disulfide bonds. This conjecture was based on the observation that 
the predicted open reading frames (ORFs) of the hyperthermophilic Pyrobaculum  aerophilum 
and Aeropyrum pernix species are strongly biased toward an even number of cysteines [70]. 
Since then, they have expanded their analysis to show that hyperthermophilic members of 
the Crenarchaeota branch all contain a multitude of disulfide-bonded proteins [68]. Mass 
spectrometric analysis of the proteome of Sulfolobus solfataricus revealed the majority of cyste-
ines to be disulfide bonded [71], and several disulfide-bonded proteins were  identified using 
2D gel analysis of lysates of P. aerophilum [72]. The presence of a high number of  disulfide 
bond-containing proteins in hyperthermophilic Crenarchaeota suggested these  bacteria 
 possess an undiscovered method of disulfide-bond maintenance. Indeed,  experimental 
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 evidence of such a system was obtained from the in vitro characterization of protein disulfide 
oxidoreductases (PDO) from Pyrococcus furiosus [73], Aquifex aeolicus [74], A. pernix [75], and 
S. solfataricus [76]. PDOs have been shown to be functional homologs of PDI and DsbC, that 
exhibit reduction, oxidation, and isomerization of disulfide bonds. Although there is growing 
evidence that the cytoplasm of Crenarchaeota is more amenable to disulfide-bond formation, 
the exact mechanism and the enzymes involved remain to be elucidated in vivo.
The method of predicting redox biology of organisms by simply analyzing the cysteine 
content of the predicted ORFs from sequenced genomes was expanded to all prokaryotic 
organisms with known genome sequences. By separating the predicted proteome into two 
subgroups—proteins predicted to be exported and those that remained in the cytoplasm—
this bioinformatic method was further developed to predict whether the periplasmic space 
was oxidizing or reducing [77]. This method led to the observation that some bacteria pre-
dicted to have an oxidizing periplasm encode a homolog of DsbA but lack a homolog of its 
partner DsbB. A closer look at these strains revealed that the DsbA homolog in Mycobacterium 
was a fusion protein to vitamin K epoxide reductase (VKOR) [77]. Characterization of bacte-
rial VKOR homologs confirmed that VKOR can indeed functionally replace DsbB in certain 
organisms [78, 79]. To our knowledge, this was the first use of genomic data to mine for new 
oxidoreductases, leading to the discovery of VKOR as a functional homolog of DsbB.
4.2. Selecting for new oxidoreductases using living bacteria
The advent of modern biomolecular tools, in conjunction with classical bacterial genetic 
screens, has led to the discovery of novel enzymes, yielded many new insights into biochemi-
cal pathways, and elucidated molecular mechanisms. The discovery that disulfide bonds are 
not formed spontaneously but are, in fact, formed catalytically by the enzyme DsbA was a 
serendipitous discovery using a blue/white screen for secretion defects [28]. The malF-lacZ 
fusion has been used to not only discover DsbA [28] but also mutants of DsbA with vari-
ous kinetic properties [31]. Since then, many other genetic screens have been developed to 
specifically detect the activity of an oxidoreductase in E. coli. These screens, described briefly 
below, allow for the selection of gene products whose activities permit the growth of strains 
in the absence of a dsb component. Characterization of mutant strains revealed insight into 
the molecular machinery of disulfide-bond formation and highlighted the plasticity of the dsb 
machinery. A few key mutations could convert a dedicated reductase into an oxidase or create 
novel pathways to maintain cell viability.
FlgI is a protein component of the flagellar machinery and requires a disulfide bond for 
its correct folding and activity [80]. Strains that have a functional disulfide-bond forming 
pathway are motile, while those with defects in disulfide-bond formation are not. By simply 
spotting bacteria incapable of forming disulfide bonds on dilute agar, researchers are able to 
screen and select for bacteria that have gained the ability to form disulfide bonds, since they 
become motile and swim away from the center. This phenotype has been used to characterize 
and select for new disulfide bond oxidases, such as selecting for mutant thioredoxins possess-
ing a new mechanism of disulfide-bond formation in the periplasm [81]. In another approach, 
researchers screened a multicopy plasmid library of E. coli and selected a  rhodanese protein 
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(PspE) with a single cysteine that can promote disulfide-bond formation in a strain completely 
lacking the dsb pathway [82].
Heavy metals such as copper or cadmium can oxidize thiol groups in periplasmic proteins, 
resulting in misfolding of proteins containing cysteines and, in some cases, leading to death 
[83]. DsbC can reduce and refold proteins that were misoxidized by such metals and is there-
fore necessary to protect cells from copper and cadmium-induced oxidative damage. This 
phenotype was used to select for strains containing mutant DsbG proteins that have gained 
the ability to isomerize misoxidized proteins [84]. In another heavy metal screen, cells lack-
ing the dsbA gene were screened for cadmium resistance to select for mutant DsbB that can 
bypass the need for DsbA [85]. The mutant DsbB proteins were able to oxidize DsbC and thus 
promote disulfide-bond formation.
A blue/white screen was developed using a mutant alkaline phosphatase (phoA*) that required 
DsbC for its correct folding and activity. Unlike DsbC, DsbG cannot isomerize misoxidized 
PhoA*. Mutants of dsbG were selected for their gained ability to isomerize PhoA*, resulting in 
the first in vivo screen that directly detected disulfide-bond isomerization of a single protein. 
This screen permitted the identification of key residues that converted a sulfenic acid reduc-
tase (DsbG) into a disulfide-bond isomerase whose activity increased the cells’ resistance to 
copper. Searching the genomes of sequenced prokaryotes, homologs of DsbG were discov-
ered to naturally have the key residues identified through the phoA* screen. Interestingly, 
these naturally existing homologs were also capable of protecting cells against copper toxic-
ity. Thus, through the identification of these key residues, activities of homologs can be pre-
dicted and tested [86].
The study of disulfide-bond formation has grown and matured significantly since the discovery of 
DsbA in 1991 [28]. Subsequently, the Dsb pathway in the model organism E. coli has been studied 
in great detail both in vivo and in vitro, and many novel and interesting mutants and suppressors 
have been identified using various in vivo screens. These new enzymes should have applications 
in both biotechnology and the pharmaceutical industry as detailed in the next section.
4.3. Biotechnological applications of disulfide-bonded proteins
Both the pharmaceutical and the biotechnological industries are extremely interested in disul-
fide-bonded proteins. Most eukaryotic cell surface and secreted proteins are rich in disulfide 
bonds due to the increased stability they confer, making these proteins attractive candidates 
as therapeutics (also known as biologics). For example, the first recombinant biologic was 
the hormone insulin, which was introduced by Eli Lilly in 1982, and the most profitable bio-
logic is the antibody Humira (adalimumab), both of which are disulfide-bonded proteins 
[87]. Between 1982 and 2013, approximately 100 recombinant protein therapeutics have been 
approved by the FDA, of which more than one-third are disulfide-bonded proteins (in par-
ticular monoclonal antibodies) [88].
Currently, antibodies represent the fastest growing category of biologics. Their specificity to 
therapeutic targets, ability to induce or inhibit immune response, and favorable pharmacoki-
netic profiles within the human body make them attractive therapeutics. The first therapeutic 
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monoclonal antibody product, Orthoclone OKT3 (muromonab-CD3), was FDA approved in 
1986. Since then, research and development of biologics has led to many successful therapeu-
tics, with projected sales expected to reach nearly $125 billion by 2020 [89] (see Table 1 for top 
11 best-selling biologics in 2013 [90]). The production of antibodies for therapeutic applica-
tions is a well-established pipeline dominated by the use of Chinese hamster ovary (CHO) 
cells or hybridomas. However, identifying, characterizing, and engineering therapeutic anti-
bodies are still expensive, time-consuming, and effortful endeavors, leaving room for these 
aspects of biologic development to be streamlined.
Name Lead  
company
Molecule  
type
Approved indication(s) 2013 worldwide 
sales  
($ millions)
Humira (adalimumab) AbbVie mAb RA, juvenile RA, Crohn’s disease, PA,  
psoriasis, ankylosing spondylitis, UC
10,659
Enbrel (etanercept) Amgen Protein RA, psoriasis, ankylosing spondylitis, PA 
juvenile RA
8739
Lantus (insulin 
glargine)
Sanofi Peptide Diabetes mellitus type I, diabetes mellitus  
type II
7593
Rituxan (rituximab) Roche mAb RA, chronic, lymphocytic leukemia/small 
cell lymphocytic lymphoma, non-Hodgkin’s 
lymphoma, antineutrophil cytoplasmic 
antibodies-associated vasculitis, indolent non-
Hodgkin’s lymphoma, diffuse large  
B-cell lymphoma
7500
Remicade (infliximab) Johnson & 
Johnson
mAb RA, Crohn’s disease, psoriasis, UC, ankylosing 
spondylitis, PA
6962
Avastin (bevacizumab) Roche mAb Colorectal cancer, non-small cell lung cancer, 
renal cell cancer, brain cancer (malignant 
glioma; AA and GBM)
6747
Herceptin 
(trastuzumab)
Roche mAb Breast cancer, gastric cancer 6558
Gleevec (imatinib) Novartis Small 
molecule
Chronic myelogenous leukemia, 
gastrointestinal stromal tumor, acute 
lymphocytic leukemia, hypereosinophilic 
syndrome, mastocytosis, dermatofibrosarcoma 
protuberans, myelodys plastic syndrome, 
myeloproliferative disorders
4693
Neulasta 
(pegfilgrastim)
Amgen Protein Neutropenia/leukopenia 4392
Copaxone (glatiramer 
acetate)
Teva Pharma-
ceutical
Peptide Multiple sclerosis 4356
Revlimid 
(lenalidomide)
Celgene Small 
molecule
Multiple myeloma, myelodysplastic syndrome, 
mantle cell lymphoma
4281
Abbreviations: mAb, monoclonal antibody; RA, rheumatoid arthritis; PA, psoriatic arthritis; UC, ulcerative colitis; AA, 
anaplastic astrocytoma; GBM, glioblastoma multiforme. Adapted from Ref. [90].
Table 1. The top 10 best selling biologics in 2013. Of these 11 biologics, five are antibody-based therapeutics, indicated 
by the mAb under molecule type.
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The use of E. coli as the most popular host for recombinant engineering of proteins stems 
from the bevy of powerful genetic tools available, its cost effectiveness, and the short time 
frames required for both its growth and genetic experiments. The periplasm, where condi-
tions favor oxidized proteins, was the clear compartment to express various antibody frag-
ments, including full-length antibodies, versus the reducing conditions of the cytoplasm [91, 
92]. The periplasmic space remains an attractive alternative for the production of disulfide-
bonded proteins whose presence/activities may be toxic when expressed in the cytoplasm 
[93]. However, translocation of the target protein across the inner membrane to the periplasm 
can be problematic and may require extensive optimization of both the expression conditions 
and the targeting signal sequence. Furthermore, the lack of ATP in the periplasm makes it 
an energy-poor environment for proteins that require ATP-dependent chaperones for their 
folding. The cytoplasm is therefore a more suitable compartment for high-yielding protein 
production. It also obviates the problem of crossing the membrane and is rich in ATP, chap-
erones, and folding factors.
With the introduction of the ΔtrxB, gor engineered strains of E. coli [94, 95], it is now possible to 
not only express various antibody fragments but also full-length antibodies in the cytoplasm 
[96]. Yet, the lack of N-linked glycosylation in E. coli has hampered its use in the production of 
therapeutic immunoglobulins (IgGs), although a few examples of E. coli-produced therapeutic 
antibody fragments can be found, such as the Fab’ fragment named Lucentis (ranibizumab) 
against age-related macular degeneration [97]. The discovery of mutations in the Fc portion of 
IgG that circumvent the dependency on glycosylation for effective interaction with its cognate 
Fcγ receptor [98] opened the path to potential therapeutic applications of E. coli-expressed IgG 
[96]. Though E. coli is currently not as established as CHO or hybridoma cell lines for the pro-
duction of therapeutic IgG, it is slowly becoming a more common host for the production of 
antibodies. Other E. coli-based technologies, such as phage display, have had extensive use in 
the discovery and engineering of antibodies, both for the biotech and the pharmaceutical indus-
tries. The use of phage display technology to identify novel antibodies of therapeutic targets, 
such as the HIV virus coat protein, was first described in 1991 [99]. Since then, phage display 
has been used to develop novel antibody-based applications. For example, the antibody Humira 
went through extensive engineering using this technique to create an effective biologic [100].
4.4. Engineering disulfide bonds
One key feature of disulfide bonds is their ability to increase the thermostability of proteins by 
decreasing the number of conformations a protein can attain and thus lowering the conforma-
tional entropy of a protein. Secreted proteins leave the protective environment of the cell cyto-
plasm, and they are rich in disulfide bonds which help to increase their extracellular half-lives. 
These enzymes are of significant utility in the biotech industry where high-temperature pro-
cesses are often used. In some cases, disulfide bonds have been introduced into such enzymes 
to increase their thermostability [101]. Early investigations into the effects of engineered disul-
fide bonds were performed on phage lambda repressor [102], T4 lysozyme [103], and subtilisin 
[104], and later were expanded to antibodies [105] and other proteins used in the biotechnol-
ogy industry. For example, the disulfide bond engineered into the extracellular ribonuclease 
(barnase) from Bacillus amyloliquefaciens unfolds 20 times slower than wild type and 170 times 
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slower than the reduced protein [106]. It is also possible to engineer an interchain disulfide 
bond within two subunits to bring together the activities of two distinct enzymes [107].
In addition to engineering disulfide bonds into proteins, the reactivity of disulfide-bond form-
ing proteins can also be altered to provide new functionalities. For example, chimeras were 
created by fusing the disulfide-bond oxidase DsbA to the dimerization domain and α-helical 
linker derived from the bacterial proline cis/trans isomerase FkpA. These chimeras were 
capable of catalyzing the in vivo isomerization of misoxidized disulfide bonds with similar 
efficiency as that of DsbC [108]. The DsbA-FkpA chimeras also conferred modest resistance 
to CuCl2, which is dependent on disulfide-bond isomerization. This resistance allowed for the selection of DsbA-FkpA mutants which were found to contain a single amino acid variation 
in the active site of DsbA from CPHC to CPYC. Substitution of histidine with tyrosine made 
the active site more DsbC-like (CGYC), which could partially explain the gain of DsbC-like 
isomerization activity. Interestingly, DsbC is not a substrate for the DsbA-DsbB oxidation sys-
tem and does not exhibit disulfide-bond oxidase activity. However, the DsbA-FkpA chime-
ras exhibited both oxidase and isomerization functionalities, and dsbA deletion strains were 
partially complemented by the presence of the DsbB-dependent DsbA-FkpA chimeras [108].
4.5. Dsb enzymes as novel antimicrobial targets
Many pathogenic bacteria, including Vibrio cholerae, Pseudomonas aeruginosa, Salmonella 
enterica, Helicobacter pylori, Bordetella pertussis, and E. coli, among others, make use of periplas-
mic disulfide-bonded proteins that act as virulence factors or function in processes related to 
their pathogenicity [109–114]. These virulence factors and pathogenic functions rely on the 
Dsb proteins, in particular DsbA, for proper folding. As a consequence, disruptions in the 
redox and isomerization activities of the dsb system partially or fully attenuate the pathoge-
nicity of these bacterial species [115]. Specifically, maturation of toxins of V. cholerae, B. pertus-
sis, and E. coli requires the formation of DsbA-dependent disulfide bonds [109, 113, 116, 117]. 
Strains of these bacteria lacking dsbA synthesize misfolded, misassembled, and/or unstable 
toxin proteins that are severely impaired or nonfunctional. Along these lines, ΔdsbA strains of 
S. enterica and E. coli lack the flagellin (FliC) protein, which is a primary constituent of the fila-
ments of their flagella. FliC does not contain any disulfide bonds. However, due to the hier-
archical assembly of the flagellum machinery, which requires several proteins with disulfide 
bonds to precede FliC in its biogenesis, it is thought that FliC simply is not translated or that 
it cannot be assembled into the organelle due to the missing disulfide bonds and/or disulfide-
bonded proteins [50, 118]. As a result, these ΔdsbA strains of S. enterica and E. coli bacteria are 
nonmotile and their pathogenicity is severely attenuated. Additionally, the loss of disulfide 
bonds in ΔdsbA strains of V. cholerae and E. coli affects their ability to adhere to eukaryotic cells 
and/or form biofilms due to defects in their pili, thereby limiting their infectivity [109, 119, 
120]. All together, these studies showed that the Dsb enzymes, especially DsbA, play crucial 
roles in the pathogenicity of several species of bacteria, making these enzymes logical targets 
for novel antibiotic development.
Indeed, some research has focused on the development of small molecule inhibitors of Dsb 
enzymes and their homologs (reviewed in Refs. [121, 122]). In humans, blood coagulation 
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involves the activity of the enzyme vitamin K epoxide reductase (VKOR), which is inhib-
ited by the anticoagulant drug warfarin (Coumadin). Interestingly, Mycobacterium tuberculosis 
(Mtb) and other bacteria do not encode for a DsbB protein, but instead encode a homolog 
of VKOR. Although DsbB and VKOR exhibit little sequence similarity, they appear to be 
functionally similar, since VKOR can replace DsbB in both E. coli and cyanobacterial ΔdsbB 
strains [77, 123]. Warfarin was shown to both inhibit MtbVKOR activity and bacterial growth. 
Furthermore, mutations in the VKOR protein from warfarin-resistant Mtb mutants were 
mapped to nearly identical locations in mutant VKORs from patients who require higher 
effective doses of warfarin, indicating the drug likely inhibits bacterial and human VKORs in 
similar manners [34]. These findings, in conjunction with the severe growth defects observed 
in MtbVKOR homolog deletion strains, suggested that stronger inhibitors of MtbVKOR could 
be used as effective antituberculosis agents [34].
Promising small molecule inhibitors of bacterial Dsb proteins have been identified using frag-
ment-based lead discovery (FBLD) [124]. FBLD identifies small molecule fragments that weakly 
bind to a target of interest. Through many rounds of iterative combinations of such fragments 
and high-throughput screening, candidate molecules with higher binding affinities for the 
target are created, leading to possible drug candidates. Using a detergent-solubilized EcDsbB 
immobilized onto sepharose resin and 1H NMR, 1071 fragments were tested for both binding 
to and inhibition of EcDsbB, yielding eight fragments exhibiting IC50 values of 7–170 μM. The eight fragments were divided into two groups based on their molecular scaffolds and hypoth-
esized mechanisms of inhibition: blocking of quinone binding and blocking of both quinone 
and EcDsbA binding to DsbB [124]. A further study improved the IC50 value of a candidate molecule to 1.1 μM through additional rounds of FBLD. This molecule inhibited both EcDsbA 
and DsbB through covalent modification of active site cysteine residue in each protein with a 
propionyl group, thereby abrogating their ability to form disulfide bonds. The molecule also 
exhibited a degree of selectivity for DsbA and DsbB proteins, since it was shown to have no 
effect on human thioredoxin activity [125].
Through the use of high-throughput blue/white screening, six additional small molecule 
inhibitors of EcDsbB were identified from a pool of approximately 52,000 compounds. 
These six molecules all contained a pyridazinone ring and exhibited a degree of selectiv-
ity for EcDsbB, since they were unable to inhibit the MtbVKOR homolog described above. 
Interestingly, the molecules inhibited DsbB enzymes from other Gram-negative pathogens, 
including V. cholerae, Haemophilus influenzae, Salmonella typhimurium, Klebsiella pneumoniae, 
Francisella tularensis, Acinetobacter baumannii, and P. aeruginosa, to varying degrees [126].
In addition to small molecules, larger peptides capable of inhibiting the formation of the 
DsbA-DsbB complex have been developed. Using the crystal structure of the DsbA-DsbB 
complex [127], a peptide of seven amino acids corresponding to a loop of DsbB involved 
in docking with DsbA was identified and found to bind to EcDsbA with low micromolar 
affinity (Kd = 13.1 ± 0.4 μM). Further engineering of this peptide resulted in a new pep-tide with greater affinity (Kd = 5.7 ± 0.4 μM) that also exhibited fairly potent inhibition of 
EcDsbA oxidase activity (IC50 = 8.8 ± 1.1 μM) [128]. The studies described herein clearly show that the  DsbA-DsbB protein system is an attractive and tractable target for novel antibiotic 
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 development. While the inhibitors described above exhibit relatively weak binding affinities, 
the resulting phenotypes observed support their disruption of disulfide-bond formation in 
the cell. These “first-generation” molecules can serve as a foundation from which more potent 
compounds can be identified and developed.
5. Future directions
There are 4306 predicted E. coli K12 protein sequences present in the UniProt proteome data-
base (http://www.uniprot.org/proteomes/) [129]. An initial analysis of their compartmental-
ization within the cell using the prediction software TOPCONS2 (http://topcons.cbr.su.se/
pred/) [130] allowed us to putatively assign each of these proteins to one of three subcellular 
compartments: cytoplasmic, transmembrane in the inner membrane (referred to as trans-
membrane hereafter), or secreted. To hone in on proteins exhibiting possible oxidoreductase 
activity, the CXXC motif was used as a signature to identify 406 proteins, which showed that 
approximately 10% of all predicted E. coli proteins contain this motif, thereby demonstrating 
its relative ubiquity. Of these 406 proteins, ~75% are cytoplasmic, ~18% are transmembrane, 
and ~7% are secreted (see Table 2). The pool of non-CXXC-containing proteins comprises the 
remaining 3900 proteins, of which ~63% are cytoplasmic, ~23% are transmembrane, and ~14% 
are secreted (omitted from Table 2). The transmembrane and secreted compartments have a 
lower fraction of CXXC-containing proteins in keeping with the exclusion of cysteine residues 
from these compartments in aerobes [77]. A comparison of the non-CXXC sequence pool with 
the CXXC sequence pool shows a slight enrichment of CXXC proteins in the cytoplasm (~75%) 
versus non-CXXC cytoplasmic proteins (~63%). The distribution of CXXC and non-CXXC 
proteins in the transmembrane is similar (18 and 23%, respectively); however, about twice 
as many non-CXXC proteins are secreted (14%) compared to CXXC proteins. Approximately 
22% (90 of 406) of CXXC proteins are annotated in the UniProt data as binding metal ions or as 
iron-sulfur cluster-containing proteins. While 46% of all CXXC proteins have been function-
ally characterized, the remaining majority (54%) should be characterized to develop a better 
understanding of the reactions they catalyze, how those identified to be oxidoreductases may 
contribute to the redox biology of bacteria, and to identify novel targets for therapeutics.
Compartment Number of proteins Contain CXXC Known function Unknown function Metal binding
Cytoplasm 2755 64% 305 75% 147 78% 158 72% 79 88%
Transmembrane 970 23% 72 18% 33 18% 39 18% 7 8%
Secreted 581 13% 29 7% 8 4% 21 10% 4 4%
Total 4306 100% 406 100% 188 100% 218 100% 90 100%
Secreted refers to proteins in the periplasm and secreted outside of the cell. Compartment location was predicted using 
topological and signal sequence input data on the TOPCONS server. Gene ontology (GO) codes EXP and IDA were used 
to identify proteins with experimentally verified function from the UniProt database; those lacking these codes were 
defined as having unknown function. GO codes were also used to identify CXXC proteins annotated to bind metals 
[129].
Table 2. The E. coli proteome separated by compartment, the presence of CXXC motifs, and known function.
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6. Conclusions
While more than 20 years of research have elucidated many of the Dsb proteins and their 
functions, more questions surrounding these proteins remain to be answered: What are the 
precise mechanisms by which PDI and DsbC catalyze disulfide-bond isomerization in vivo? 
How are electrons transported across the inner membrane by DsbD? What are the redox 
states and midpoint potentials of the cytoplasm of Crenarchaeota? Additionally, most of the 
characterization of Dsb proteins has been done in E. coli, which is not an appropriate model 
for all bacteria, e.g., M. tuberculosis, Staphylococcus aureus, and Listeria monocytogenes, so further 
characterization of the Dsb protein networks in other organisms is needed. Along these lines, 
Dsb proteins from pathogenic bacteria represent possible targets for antibiotic/vaccine devel-
opment. Since several Dsb proteins have been structurally characterized, it is now possible to 
develop antibiotics by structure-guided design. While broad-spectrum antibiotic molecules 
are unlikely to be developed, again due to the diversity of Dsb proteins/networks within bac-
terial species, those targeting specific pathogenic species are not out of reach.
As more disulfide-bonded proteins are characterized, our knowledge of the stability and 
structures these bonds confer, their likelihood of scrambling in mulitply disulfide-bonded 
proteins, and their relative redox potentials will grow. This will allow researchers to better 
predict native disulfide bonds from sequence data and better engineer disulfide bonds in pro-
teins for desirable physicochemical properties, which will benefit both the biotechnological 
and pharmaceutical industries, especially in the development and production of antibodies. 
Ideally, both industries should aim to produce antibodies as quickly, cheaply, and effectively 
as possible. The engineering of bacterial strains to overproduce correctly folded antibodies 
and/or engineering antibodies themselves for desired properties represents a technically 
challenging but incredibly useful advancement in the field of oxidative protein folding. 
Future research in these areas should lead to great innovations in both the biotechnological 
and pharmaceutical industries that will improve the health and increase the knowledge of 
humankind.
Author details
Bradley J. Landgraf1, Guoping Ren1, Thorsten Masuch1, Dana Boyd2 and Mehmet Berkmen1*
*Address all correspondence to: berkmen@neb.com
1 New England Biolabs / Ruhr-Universität Bochum, Germany
2 Department of Microbiology and Immunology, Harvard Medical School, Boston, MA, USA
References
[1] Lee C, Lee SM, Mukhopadhyay P, Kim SJ, Lee SC, et al. 2004. Redox regulation of OxyR 
requires specific disulfide bond formation involving a rapid kinetic reaction path. Nat. 
Struct. Mol. Biol. 11: 1179-85.
From Biology to Biotechnology: Disulfide Bond Formation in Escherichia coli
http://dx.doi.org/10.5772/67393
373
[2] Alvarez FA, Georgellis D. 2010. In vitro and in vivo analysis of the ArcB/A redox signal-
ing pathway. Methods Enzymol. 471: 205-26.
[3] Kang JG, Paget MS, Seok YJ, Hahn MY, Bae JB, et al. 1999. RsrA, an anti-sigma factor 
regulated by redox change. EMBO J. 18: 4292-8.
[4] Jander G, Martin NL, Beckwith J. 1994. Two cysteines in each periplasmic domain of the 
membrane protein DsbB are required for its function in protein disulfide bond forma-
tion. EMBO J. 13: 5121-7.
[5] Andersen CL, Matthey-Dupraz A, Missiakas D, Raina S. 1997. A new Escherichia coli 
gene, dsbG, encodes a periplasmic protein involved in disulphide bond formation, 
required for recycling DsbA/DsbB and DsbC redox proteins. Mol. Microbiol. 26: 121-32.
[6] Gon S, Faulkner MJ, Beckwith J. 2006. In vivo requirement for glutaredoxins and thio-
redoxins in the reduction of the ribonucleotide reductases of Escherichia coli. Antioxid. 
Redox Signal. 8: 735-42.
[7] Klink TA, Woycechowsky KJ, Taylor KM, Raines RT. 2000. Contribution of disulfide 
bonds to the conformational stability and catalytic activity of ribonuclease A. Eur. J. 
Biochem. 267: 566-72.
[8] Kunitz M, McDonald MR. 1953. Biochem. Prep. 3: 9.
[9] Flory PJ. 1956. Theory of elastic mechanisms in fibrous proteins. J. Am. Chem. Soc. 78: 
5222-35.
[10] Pfeil W. 1981. The problem of the stability of globular proteins Mol. Cell. Biochem. 40: 
3-28.
[11] Konishi Y, Ooi T, Scheraga HA. 1982. Regeneration of ribonuclease A from the reduced 
protein. 2. Energetic analysis. Biochemistry 21: 4741-8.
[12] White FH, Jr. 1960. Regeneration of enzymatic activity by air oxidation of reduced ribo-
nuclease with observations on thiolation during reduction with thioglycolate. J. Biol. 
Chem. 235: 383-9.
[13] Haber E, Anfinsen CB. 1961. Regeneration of enzyme activity by air oxidation of reduced 
subtilisin-modified ribonuclease. J. Biol. Chem. 236: 422-4.
[14] Anfinsen CB, Haber E. 1961. Studies on the reduction and re-formation of protein disul-
fide bonds. J. Biol. Chem. 236: 1361-3.
[15] Anfinsen CB, Haber E, Sela M, White FH, Jr. 1961. The kinetics of formation of native 
ribonuclease during oxidation of the reduced polypeptide chain. Proc. Natl. Acad. Sci. 
U. S. A. 47: 1309-14.
[16] Goldberger RF, Epstein CJ, Anfinsen CB. 1963. Acceleration of reactivation of reduced bovine 
pancreatic ribonuclease by a microsomal system from rat liver. J. Biol. Chem. 238: 628-35.
[17] Venetianer P, Straub FB. 1963. The enzymic reactivation of reduced ribonuclease. 
Biochim. Biophys. Acta (BBA) Spec. Sec. Enzymol. Subj. 67: 166-8.
Escherichia coli - Recent Advances on Physiology, Pathogenesis and Biotechnological Applications374
[18] Goldberger RF, Epstein CJ, Anfinsen CB. 1964. Purification and properties of a micro-
somal enzyme system catalyzing the reactivation of reduced ribonuclease and lysozyme. 
J. Biol. Chem. 239: 1406-10.
[19] De Lorenzo F, Goldberger RF, Steers E, Jr., Givol D, Anfinsen B. 1966. Purification and 
properties of an enzyme from beef liver which catalyzes sulfhydryl-disulfide inter-
change in proteins. J. Biol. Chem. 241: 1562-7.
[20] Fuchs S, De Lorenzo F, Anfinsen CB. 1967. Studies on the mechanism of the enzymic 
catalysis of disulfide interchange in proteins. J. Biol. Chem. 242: 398-402.
[21] Brockway BE, Forster SJ, Freedman RB. 1980. Protein disulphide-isomerase activity in chick-
embryo tissues. Correlation with the biosynthesis of procollagen. Biochem. J. 191: 873-6.
[22] Roth RA, Koshland ME. 1981. Role of disulfide interchange enzyme in immunoglobulin 
synthesis. Biochemistry 20: 6594-9.
[23] Lambert N, Freedman RB. 1983. Structural properties of homogeneous protein disulphide-
isomerase from bovine liver purified by a rapid high-yielding procedure. Biochem. J. 213: 
225-34.
[24] Lambert N, Freedman RB. 1983. Kinetics and specificity of homogeneous protein disul-
phide-isomerase in protein disulphide isomerization and in thiol-protein-disulphide 
oxidoreduction. Biochem. J. 213: 235-43.
[25] Sanger F, Coulson AR. 1975. A rapid method for determining sequences in DNA by 
primed synthesis with DNA polymerase. J. Mol. Biol. 94: 441-8.
[26] Sanger F, Nicklen S, Coulson AR. 1977. DNA sequencing with chain-terminating inhibi-
tors. Proc. Natl. Acad. Sci. 74: 5463-7.
[27] Saiki R, Scharf S, Faloona F, Mullis K, Horn G, et al. 1985. Enzymatic amplification of 
beta-globin genomic sequences and restriction site analysis for diagnosis of sickle cell 
anemia. Science 230: 1350-4.
[28] Bardwell JC, McGovern K, Beckwith J. 1991. Identification of a protein required for 
disulfide bond formation in vivo. Cell 67: 581-9.
[29] Akiyama Y, Kamitani S, Kusukawa N, Ito K. 1992. In vitro catalysis of oxidative fold-
ing of disulfide-bonded proteins by the Escherichia coli dsbA (ppfA) gene product. J. Biol. 
Chem. 267: 22440-5.
[30] Bardwell JC, Lee JO, Jander G, Martin N, Belin D, Beckwith J. 1993. A pathway for disul-
fide bond formation in vivo. Proc. Natl. Acad. Sci. U. S. A. 90: 1038-42.
[31] Kadokura H, Tian H, Zander T, Bardwell JC, Beckwith J. 2004. Snapshots of DsbA in 
action: detection of proteins in the process of oxidative folding. Science 303: 534-7.
[32] Missiakas D, Georgopoulos C, Raina S. 1993. Identification and characterization of the 
Escherichia coli gene dsbB, whose product is involved in the formation of disulfide bonds 
in vivo. Proc. Natl. Acad. Sci. U. S. A. 90: 7084-8.
From Biology to Biotechnology: Disulfide Bond Formation in Escherichia coli
http://dx.doi.org/10.5772/67393
375
[33] Kishigami S, Kanaya E, Kikuchi M, Ito K. 1995. DsbA-DsbB interaction through their 
active site cysteines. Evidence from an odd cysteine mutant of DsbA. J. Biol. Chem. 270: 
17072-4.
[34] Dutton RJ, Wayman A, Wei JR, Rubin EJ, Beckwith J, Boyd D. 2010. Inhibition of bacterial 
disulfide bond formation by the anticoagulant warfarin. Proc. Natl. Acad. Sci. U. S. A. 
107: 297-301.
[35] Kadokura H, Beckwith J. 2002. Four cysteines of the membrane protein DsbB act in con-
cert to oxidize its substrate DsbA. EMBO J. 21: 2354-63.
[36] Inaba K, Takahashi YH, Fujieda N, Kano K, Miyoshi H, Ito K. 2004. DsbB elicits a red-shift 
of bound ubiquinone during the catalysis of DsbA oxidation. J. Biol. Chem. 279: 6761-8.
[37] Inaba K, Takahashi YH, Ito K. 2005. Reactivities of quinone-free DsbB from Escherichia 
coli. J. Biol. Chem. 280: 33035-44.
[38] Grauschopf U, Fritz A, Glockshuber R. 2003. Mechanism of the electron transfer catalyst 
DsbB from Escherichia coli. EMBO J. 22: 3503-13.
[39] Zeng H, Snavely I, Zamorano P, Javor GT. 1998. Low ubiquinone content in Escherichia 
coli causes thiol hypersensitivity. J. Bacteriol. 180: 3681-5.
[40] Regeimbal J, Bardwell JC. 2002. DsbB catalyzes disulfide bond formation de novo. J. Biol. 
Chem. 277: 32706-13.
[41] Regeimbal J, Gleiter S, Trumpower BL, Yu CA, Diwakar M, et al. 2003. Disulfide bond 
formation involves a quinhydrone-type charge-transfer complex. Proc. Natl. Acad. Sci. 
U. S. A. 100: 13779-84.
[42] Bader M, Muse W, Ballou DP, Gassner C, Bardwell JC. 1999. Oxidative protein folding is 
driven by the electron transport system. Cell 98: 217-27.
[43] Bader MW, Xie T, Yu CA, Bardwell JC. 2000. Disulfide bonds are generated by quinone 
reduction. J. Biol. Chem. 275: 26082-8.
[44] Collet JF, Bardwell JC. 2002. Oxidative protein folding in bacteria. Mol. Microbiol. 44: 1-8.
[45] Kobayashi T, Kishigami S, Sone M, Inokuchi H, Mogi T, Ito K. 1997. Respiratory chain is 
required to maintain oxidized states of the DsbA-DsbB disulfide bond formation system 
in aerobically growing Escherichia coli cells. Proc. Natl. Acad. Sci. U. S. A. 94: 11857-62.
[46] Kobayashi T, Ito K. 1999. Respiratory chain strongly oxidizes the CXXC motif of DsbB in 
the Escherichia coli disulfide bond formation pathway. EMBO J. 18: 1192-8.
[47] Missiakas D, Georgopoulos C, Raina S. 1994. The Escherichia coli dsbC (xprA) gene encodes 
a periplasmic protein involved in disulfide bond formation. EMBO J. 13: 2013-20.
[48] Berkmen M, Boyd D, Beckwith J. 2005. The nonconsecutive disulfide bond of Escherichia 
coli phytase (AppA) renders it dependent on the protein-disulfide isomerase, DsbC. J. 
Biol. Chem. 280: 11387-94.
Escherichia coli - Recent Advances on Physiology, Pathogenesis and Biotechnological Applications376
[49] Bessette PH, Qiu J, Bardwell JC, Swartz JR, Georgiou G. 2001. Effect of sequences of the 
active-site dipeptides of DsbA and DsbC on in vivo folding of multidisulfide proteins in 
Escherichia coli. J. Bacteriol. 183: 980-8.
[50] Hiniker A, Bardwell JC. 2004. In vivo substrate specificity of periplasmic disulfide 
 oxidoreductases. J. Biol. Chem. 279: 12967-73.
[51] Joly JC, Swartz JR. 1997. In vitro and in vivo redox states of the Escherichia coli periplasmic 
oxidoreductases DsbA and DsbC. Biochemistry 36: 10067-72.
[52] Shouldice SR, Cho SH, Boyd D, Heras B, Eser M, et al. 2010. In vivo oxidative protein 
folding can be facilitated by oxidation-reduction cycling. Mol. Microbiol. 75: 13-28.
[53] Chung J, Chen T, Missiakas D. 2000. Transfer of electrons across the cytoplasmic 
 membrane by DsbD, a membrane protein involved in thiol-disulphide exchange and 
protein folding in the bacterial periplasm. Mol. Microbiol. 35: 1099-109.
[54] Bessette PH, Cotto JJ, Gilbert HF, Georgiou G. 1999. In vivo and in vitro function of the 
Escherichia coli periplasmic cysteine oxidoreductase DsbG. J. Biol. Chem. 274: 7784-92.
[55] Missiakas D, Schwager F, Raina S. 1995. Identification and characterization of a new 
disulfide isomerase-like protein (DsbD) in Escherichia coli. EMBO J. 14: 3415-24.
[56] Stewart EJ, Katzen F, Beckwith J. 1999. Six conserved cysteines of the membrane protein 
DsbD are required for the transfer of electrons from the cytoplasm to the periplasm of 
Escherichia coli. EMBO J. 18: 5963-71.
[57] Rietsch A, Belin D, Martin N, Beckwith J. 1996. An in vivo pathway for disulfide bond 
isomerization in Escherichia coli. Proc. Natl. Acad. Sci. U. S. A. 93: 13048-53.
[58] Rietsch A, Bessette P, Georgiou G, Beckwith J. 1997. Reduction of the periplasmic disul-
fide bond isomerase, DsbC, occurs by passage of electrons from cytoplasmic thiore-
doxin. J. Bacteriol. 179: 6602-8.
[59] Katzen F, Beckwith J. 2000. Transmembrane electron transfer by the membrane protein 
DsbD occurs via a disulfide bond cascade. Cell 103: 769-79.
[60] Goldstone D, Haebel PW, Katzen F, Bader MW, Bardwell JC, et al. 2001. DsbC activation 
by the N-terminal domain of DsbD. Proc. Natl. Acad. Sci. U. S. A. 98: 9551-6.
[61] Haebel PW, Goldstone D, Katzen F, Beckwith J, Metcalf P. 2002. The disulfide bond 
isomerase DsbC is activated by an immunoglobulin-fold thiol oxidoreductase: crystal 
structure of the DsbC-DsbDalpha complex. EMBO J. 21: 4774-84.
[62] Goulding CW, Sawaya MR, Parseghian A, Lim V, Eisenberg D, Missiakas D. 2002. 
 Thiol-disulfide exchange in an immunoglobulin-like fold: structure of the N-terminal 
domain of DsbD. Biochemistry 41: 6920-7.
[63] Rozhkova A, Stirnimann CU, Frei P, Grauschopf U, Brunisholz R, et al. 2004. Structural 
basis and kinetics of inter- and intramolecular disulfide exchange in the redox catalyst 
DsbD. EMBO J. 23: 1709-19.
From Biology to Biotechnology: Disulfide Bond Formation in Escherichia coli
http://dx.doi.org/10.5772/67393
377
[64] Hayden EC. 2014. Technology: the $1000 genome. Nature 507: 294-5.
[65] Land M, Hauser L, Jun S-R, Nookaew I, Leuze MR, et al. 2015. Insights from 20 years of 
bacterial genome sequencing. Funct. Integr. Genom. 15: 141-61.
[66] Köser CU, Holden MTG, Ellington MJ, Cartwright EJP, Brown NM, et al. 2012. Rapid 
whole-genome sequencing for investigation of a neonatal MRSA outbreak. New Engl. J. 
Med. 366: 2267-75.
[67] Harris SR, Cartwright EJP, Török ME, Holden MTG, Brown NM, et al. 2013. Whole-
genome sequencing for analysis of an outbreak of meticillin-resistant Staphylococcus 
aureus: a descriptive study. Lancet Infect. Dis. 13: 130-6.
[68] Jorda J, Yeates TO. 2011. Widespread disulfide bonding in proteins from thermophilic 
archaea. Archaea 2011: 409156.
[69] Beeby M, O'Connor BD, Ryttersgaard C, Boutz DR, Perry LJ, Yeates TO. 2005. The genom-
ics of disulfide bonding and protein stabilization in thermophiles. PLoS Biol. 3: e309.
[70] Mallick P, Boutz DR, Eisenberg D, Yeates TO. 2002. Genomic evidence that the intracel-
lular proteins of archaeal microbes contain disulfide bonds. Proc. Natl. Acad. Sci. U. S. A. 
99: 9679-84.
[71] Heinemann J, Hamerly T, Maaty WS, Movahed N, Steffens JD, et al. 2014. Expanding the 
paradigm of thiol redox in the thermophilic root of life. Biochim. Biophys. Acta 1840: 80-5.
[72] Boutz DR, Cascio D, Whitelegge J, Perry LJ, Yeates TO. 2007. Discovery of a thermophilic 
protein complex stabilized by topologically interlinked chains. J. Mol. Biol. 368: 1332-44.
[73] Pedone E, Ren B, Ladenstein R, Rossi M, Bartolucci S. 2004. Functional properties of the 
protein disulfide oxidoreductase from the archaeon Pyrococcus furiosus: a member of a 
novel protein family related to protein disulfide-isomerase. Eur. J. Biochem. 271: 3437-48.
[74] Pedone E, D'Ambrosio K, De Simone G, Rossi M, Pedone C, Bartolucci S. 2006. Insights 
on a new PDI-like family: structural and functional analysis of a protein disulfide 
 oxidoreductase from the bacterium Aquifex aeolicus. J. Mol. Biol. 356: 155-64.
[75] D'Ambrosio K, Pedone E, Langella E, De Simone G, Rossi M, et al. 2006. A novel  member 
of the protein disulfide oxidoreductase family from Aeropyrum pernix K1: structure, 
function and electrostatics. J. Mol. Biol. 362: 743-52.
[76] Pedone E, Limauro D, D'Alterio R, Rossi M, Bartolucci S. 2006. Characterization of a 
multifunctional protein disulfide oxidoreductase from Sulfolobus solfataricus. FEBS J. 273: 
5407-20.
[77] Dutton RJ, Boyd D, Berkmen M, Beckwith J. 2008. Bacterial species exhibit diversity in 
their mechanisms and capacity for protein disulfide bond formation. Proc. Natl. Acad. 
Sci. U. S. A. 105: 11933-8.
[78] Wang X, Dutton RJ, Beckwith J, Boyd D. 2011. Membrane topology and mutational  analysis 
of Mycobacterium tuberculosis VKOR, a protein involved in disulfide bond formation and a 
homologue of human vitamin K epoxide reductase. Antioxid. Redox Signal. 14: 1413-20.
Escherichia coli - Recent Advances on Physiology, Pathogenesis and Biotechnological Applications378
[79] Li W, Schulman S, Dutton RJ, Boyd D, Beckwith J, Rapoport TA. 2010. Structure of a 
bacterial homolog of vitamin K epoxide reductase. Nature 463: 507-12.
[80] Dailey FE, Berg HC. 1993. Mutants in disulfide bond formation that disrupt flagellar 
assembly in Escherichia coli. Proc. Natl. Acad. Sci. U. S. A. 90: 1043-7.
[81] Masip L, Pan JL, Haldar S, Penner-Hahn JE, DeLisa MP, et al. 2004. An engineered 
 pathway for the formation of protein disulfide bonds. Science 303: 1185-9.
[82] Chng SS, Dutton RJ, Denoncin K, Vertommen D, Collet JF, et al. 2012. Overexpression 
of the rhodanese PspE, a single cysteine-containing protein, restores disulphide bond 
formation to an Escherichia coli strain lacking DsbA. Mol. Microbiol. 85: 996-1006.
[83] Rensing C, Mitra B, Rosen BP. 1997. Insertional inactivation of dsbA produces sensitivity 
to cadmium and zinc in Escherichia coli. J. Bacteriol. 179: 2769-71.
[84] Hiniker A, Ren G, Heras B, Zheng Y, Laurinec S, et al. 2007. Laboratory evolution of one 
disulfide isomerase to resemble another. Proc. Natl. Acad. Sci. U. S. A. 104: 11670-5.
[85] Pan JL, Sliskovic I, Bardwell JC. 2008. Mutants in DsbB that appear to redirect oxidation 
through the disulfide isomerization pathway. J. Mol. Biol. 377: 1433-42.
[86] Chatelle C, Kraemer S, Ren G, Chmura H, Marechal N, et al. 2015. Converting a sulfenic 
acid reductase into a disulfide bond isomerase. Antioxid. Redox Signal. 23: 945-57.
[87] Zhang L, Chou CP, Moo-Young M. 2011. Disulfide bond formation and its impact on 
the biological activity and stability of recombinant therapeutic proteins produced by 
Escherichia coli expression system. Biotechnol. Adv. 29: 923-9.
[88] Kinch MS. 2015. An overview of FDA-approved biologics medicines. Drug Discov. Today 
20: 393-8.
[89] Ecker DM, Jones SD, Levine HL. 2015. The therapeutic monoclonal antibody market 
mAbs 7: 9-14.
[90] Lawrence S, Lahteenmaki R. 2014. Public biotech 2013[mdash]the numbers. Nat. 
Biotechnol. 32: 626-32.
[91] Lee YJ, Lee DH, Jeong KJ. 2014. Enhanced production of human full-length immuno-
globulin G1 in the periplasm of Escherichia coli. Appl. Microbiol. Biotechnol. 98: 1237-46.
[92] Zhou Y, Liu P, Gan Y, Sandoval W, Katakam AK, et al. 2016. Enhancing full-length 
 antibody production by signal peptide engineering. Microb. Cell Fact. 15: 47.
[93] Yoon SH, Kim SK, Kim JF. 2010. Secretory production of recombinant proteins in 
Escherichia coli. Recent Pat. Biotechnol. 4: 23-9.
[94] Lobstein J, Emrich CA, Jeans C, Faulkner M, Riggs P, Berkmen M. 2012. SHuffle, a novel 
Escherichia coli protein expression strain capable of correctly folding disulfide bonded 
proteins in its cytoplasm. Microb. Cell Fact. 11: 56.
From Biology to Biotechnology: Disulfide Bond Formation in Escherichia coli
http://dx.doi.org/10.5772/67393
379
[95] Bessette PH, Aslund F, Beckwith J, Georgiou G. 1999. Efficient folding of proteins with 
multiple disulfide bonds in the Escherichia coli cytoplasm. Proc. Natl. Acad. Sci. U. S. A. 
96: 13703-8.
[96] Robinson MP, Ke N, Lobstein J, Peterson C, Szkodny A, et al. 2015. Efficient expression 
of full-length antibodies in the cytoplasm of engineered bacteria. Nat. Commun. 6: 8072.
[97] Magdelaine-Beuzelin C, Pinault C, Paintaud G, Watier H. 2010. Therapeutic antibodies 
in ophthalmology: old is new again. mAbs 2: 176-80.
[98] Mazor Y, Van Blarcom T, Mabry R, Iverson BL, Georgiou G. 2007. Isolation of engineered, 
full-length antibodies from libraries expressed in Escherichia coli. Nat. Biotechnol. 25: 563-5.
[99] Burton DR, Barbas CF, 3rd, Persson MA, Koenig S, Chanock RM, Lerner RA. 1991. A 
large array of human monoclonal antibodies to type 1 human immunodeficiency virus 
from combinatorial libraries of asymptomatic seropositive individuals. Proc. Natl. 
Acad. Sci. U. S. A. 88: 10134-7.
[100] Nixon AE, Sexton DJ, Ladner RC. 2014. Drugs derived from phage display: from candi-
date identification to clinical practice. mAbs 6: 73-85
[101] Dombkowski AA, Sultana KZ, Craig DB. 2014. Protein disulfide engineering. FEBS Lett. 
588: 206-12.
[102] Sauer RT, Hehir K, Stearman RS, Weiss MA, Jeitler-Nilsson A, et al. 1986. An engineered 
intersubunit disulfide enhances the stability and DNA binding of the N-terminal 
domain of lambda repressor. Biochemistry 25: 5992-8.
[103] Wetzel R, Perry LJ, Baase WA, Becktel WJ. 1988. Disulfide bonds and thermal stability 
in T4 lysozyme. Proc. Natl. Acad. Sci. U. S. A. 85: 401-5.
[104] Wells JA, Powers DB. 1986. In vivo formation and stability of engineered disulfide 
bonds in subtilisin. J. Biol. Chem. 261: 6564-70.
[105] Hagihara Y, Saerens D. 2014. Engineering disulfide bonds within an antibody. Biochim. 
Biophys. Acta 1844: 2016-23.
[106] Clarke J, Fersht AR. 1993. Engineered disulfide bonds as probes of the folding  pathway 
of barnase: increasing the stability of proteins against the rate of denaturation. 
Biochemistry 32: 4322-9.
[107] Heikoop JC, van den Boogaart P, Mulders JW, Grootenhuis PD. 1997. Structure-based 
design and protein engineering of intersubunit disulfide bonds in gonadotropins. Nat. 
Biotechnol. 15: 658-62.
[108] Arredondo S, Segatori L, Gilbert HF, Georgiou G. 2008. De novo design and evolution 
of artificial disulfide isomerase enzymes analogous to the bacterial DsbC. J. Biol. Chem. 
283: 31469-76.
[109] Peek JA, Taylor RK. 1992. Characterization of a periplasmic thiol: disulfide interchange 
protein required for the functional maturation of secreted virulence factors of Vibrio 
cholerae. Proc. Natl. Acad. Sci. U. S. A. 89: 6210-4.
Escherichia coli - Recent Advances on Physiology, Pathogenesis and Biotechnological Applications380
[110] Barbieri JT, Sun J. 2005. In Reviews of Physiology, Biochemistry and Pharmacology, 
pp. 79-92. Berlin, Heidelberg: Springer Berlin Heidelberg.
[111] Miki T, Okada N, Danbara H. 2004. Two periplasmic disulfide oxidoreductases, 
DsbA and SrgA, target outer membrane protein SpiA, a component of the Salmonella 
 pathogenicity island 2 type III secretion system. J. Biol. Chem. 279: 34631-42.
[112] Godlewska R, Dzwonek A, Mikuła M, Ostrowski J, Pawłowski M, et al. 2006. Helicobacter 
pylori protein oxidation influences the colonization process. Int. J. Med. Microbiol. 296: 321-4.
[113] Stenson TH, Weiss AA. 2002. DsbA and DsbC are required for secretion of pertussis 
toxin by Bordetella pertussis. Infect. Immun. 70: 2297-303.
[114] Okamoto K, Nomura T, Fujii Y, Yamanaka H. 1998. Contribution of the disulfide bond of 
the A subunit to the action of Escherichia coli heat-labile enterotoxin. J. Bacteriol. 180: 1368-74.
[115] Lasica AM, Jagusztyn-Krynicka EK. 2007. The role of Dsb proteins of Gram-negative 
bacteria in the process of pathogenesis. FEMS Microbiol. Rev. 31: 626-36.
[116] Wülfing C, Rappuoli R. 1997. Efficient production of heat-labile enterotoxin mutant 
proteins by overexpression of dsbA in a degP-deficient Escherichia coli strain. Arch. 
Microbiol. 167: 280-3.
[117] Foreman DT, Martinez Y, Coombs G, Torres A, Kupersztoch YM. 1995. TolC and DsbA 
are needed for the secretion of STB, a heat-stable enterotoxin of Escherichia coli. Mol. 
Microbiol. 18: 237-45.
[118] Agudo D, Mendoza MT, Castañares C, Nombela C, Rotger R. 2004. A proteomic 
approach to study Salmonella typhi periplasmic proteins altered by a lack of the DsbA 
thiol: disulfide isomerase. Proteomics 4: 355-63.
[119] Zhang H-Z, Donnenberg MS. 1996. DsbA is required for stability of the type IV pilin of 
enteropathogenic Escherichia coli. Mol. Microbiol. 21: 787-97.
[120] Lee Y, Kim Y, Yeom S, Kim S, Park S, et al. 2008. The role of disulfide bond isomerase A 
(DsbA) of Escherichia coli O157: H7 in biofilm formation and virulence. FEMS Microbiol. 
Lett. 278: 213-22.
[121] Smith RP, Paxman JJ, Scanlon MJ, Heras B. 2016. Targeting bacterial Dsb proteins for 
the development of anti-virulence agents. Molecules 21: 811-25.
[122] Heras B, Shouldice SR, Totsika M, Scanlon MJ, Schembri MA, Martin JL. 2009. DSB 
proteins and bacterial pathogenicity. Nat. Rev. Microbiol. 7: 215-25.
[123] Singh AK, Bhattacharyya-Pakrasi M, Pakrasi HB. 2008. Identification of an atypical 
membrane protein involved in the formation of protein disulfide bonds in oxygenic 
photosynthetic organisms. J. Biol. Chem. 283: 15762-70.
[124] Früh V, Zhou Y, Chen D, Loch C, Eiso AB, et al. 2010. Application of fragment based 
drug discovery to membrane proteins: biophysical identification of ligands of the 
 integral membrane enzyme DsbB. Chem. Biol. 17: 881-91.
From Biology to Biotechnology: Disulfide Bond Formation in Escherichia coli
http://dx.doi.org/10.5772/67393
381
[125] Halili MA, Bachu P, Lindahl F, Bechara C, Mohanty B, et al. 2015. Small molecule 
 inhibitors of disulfide bond formation by the bacterial DsbA-DsbB dual enzyme 
 system. ACS Chem. Biol. 10: 957-64.
[126] Landeta C, Blazyk JL, Hatahet F, Meehan BM, Eser M, et al. 2015. Compounds target-
ing disulfide bond forming enzyme DsbB of Gram-negative bacteria. Nat. Chem. Biol. 
11: 292-8.
[127] Inaba K, Murakami S, Suzuki M, Nakagawa A, Yamashita E, et al. 2006. Crystal  structure 
of the DsbB-DsbA complex reveals a mechanism of disulfide bond  generation. Cell 127: 
789-801.
[128] Duprez W, Premkumar L, Halili MA, Lindahl F, Reid RC, et al. 2015. Peptide inhibitors 
of the Escherichia coli DsbA oxidative machinery essential for bacterial virulence. J. Med. 
Chem. 58: 577-87.
[129] Consortium TU. 2015. UniProt: a hub for protein information. Nucleic Acids Res. 43: 
D204-12.
[130] Tsirigos KD, Peters C, Shu N, Käll L, Elofsson A. 2015. The TOPCONS web server for 
consensus prediction of membrane protein topology and signal peptides. Nucleic Acids 
Res. 43: W401-7.
Escherichia coli - Recent Advances on Physiology, Pathogenesis and Biotechnological Applications382
